Compugen Ltd. (CGEN) Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types Involved in Tumor Progression
9/17/2013 10:00:48 AM
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) today disclosed experimental data for CGEN-15049, one of nine novel immune checkpoint proteins predicted by the Company to date through the use of its unique predictive discovery infrastructure. The experimental data demonstrate CGEN-15049's expression on a wide variety of cancers, and its functional effects on the activities of multiple types of immune cells that play critical roles in the immune system's response against the tumor. These two characteristics identify CGEN-15049 as a promising target for the treatment of various cancers using monoclonal antibody therapy in order to block its inhibition of immune response against the tumor.
Help employers find you! Check out all the jobs and post your resume.
comments powered by